CoChat

The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

Erazo, Tatiana, Lorente, Mar, López-Plana, Anna, Muñoz-Guardiola, Pau, Fernández-Nogueira, Patricia, García-Martínez, José A., Bragado, Paloma, Fuster, Gemma, Salazar, María, Espadaler, Jordi, Hernández-Losa, Javier, Bayascas, Jose Ramon, Cortal, Marc, Vidal, Laura, Gascón, Pedro, Gómez-Ferreria, Mariana, Alfón, José, Velasco, Guillermo, Domènech, Carles, Lizcano, Jose M. · 2016 · Clinical Cancer Research
Cited by 76

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: ABTL0812 is a novel first-in-class, small molecule which showed antiproliferative effect on tumor cells in phenotypic assays. Here we describe the mechanism of action of this antitumor drug, which is currently in clinical development. Experimental Design: We investigated the effect of ABTL0812 on cancer cell death, proliferation, and modulation of intracellular signaling pathways, using human lung (A549) and pancreatic (MiaPaCa-2) cancer cells and tumor xenografts. To identify cellular targets, we performed in silico high-throughput screening comparing ABTL0812 chemical structure against ChEMBL15 database. Results: ABTL0812 inhibited Akt/mTORC1 axis, resulting in impaired cancer cell proliferation and autophagy-mediated cell death. In silico screening led us to identify PPARs, PPARα and PPARγ as the cellular targets of ABTL0812. We showed that ABTL0812 activates both PPAR receptors, resulting in upregulation of Tribbles-3 pseudokinase (TRIB3) gene expression. Upregulated TRIB3 binds cellular Akt, preventing its activation by upstream kinases, resulting in Akt inhibition and suppression of the Akt/mTORC1 axis. Pharmacologic inhibition of PPARα/γ or TRIB3 silencing prevented ABTL0812-induced cell death. ABTL0812 treatment induced Akt inhibition in cancer cells, tumor xenografts, and peripheral blood mononuclear cells from patients enrolled in phase I/Ib first-in-human clinical trial. Conclusions: ABTL0812 has a unique and novel mechanism of action, that defines a new and drugable cellular route that links PPARs to Akt/mTORC1 axis, where TRIB3 pseudokinase plays a central role. Activation of this route (PPARα/γ-TRIB3-Akt-mTORC1) leads to autophagy-mediated cancer cell death. Given the low toxicity and high tolerability of ABTL0812, our results support further development of ABTL0812 as a promising anticancer therapy. Clin Cancer Res; 22(10); 2508–19. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1808

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 76

Metadata

Authors
Erazo, T., Lorente, M., López-Plana, A., Muñoz-Guardiola, P., Fernández-Nogueira, P., García-Martínez, J. A., Bragado, P., Fuster, G., Salazar, M., Espadaler, J., Hernández-Losa, J., Bayascas, J. R., Cortal, M., Vidal, L., Gascón, P., Gómez-Ferreria, M., Alfón, J., Velasco, G., Domènech, C., & Lizcano, J. M.
Venue
Clinical Cancer Research
Published
2016-05-12
Volume
22
Issue
10
Pages
2508-2519
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2199216521
Cited by
76
References
7
FWCI
1.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1808
The paper
Erazo, T., Lorente, M., López-Plana, A., Muñoz-Guardiola, P., Fernández-Nogueira, P., García-Martínez, J. A., Bragado, P., Fuster, G., Salazar, M., Espadaler, J., Hernández-Losa, J., Bayascas, J. R., Cortal, M., Vidal, L., Gascón, P., Gómez-Ferreria, M., Alfón, J., Velasco, G., Domènech, C., & Lizcano, J. M. (2016). The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.